Aldeyra Therapeutics is a biotechnology company focused on discovering and developing therapies designed to treat immune-mediated diseases. Co.'s primary product candidate, reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. Co. has additional product candidates in development for autoimmune diseases and other immune-mediated disease, as well as for proliferative vitreoretinopathy (PVR) and other retinal diseases. Co. has rights to ADX-2191, a vitreous-compatible methotrexate formulation for intraocular injection, for the prevention of PVR, a retinal disease, and primary vitreoretinal lymphoma, a rare cancer. We show 33 historical shares outstanding datapoints in our ALDX shares outstanding history coverage, used to compute ALDX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ALDX market cap history over the course of time is important for investors
interested in comparing ALDX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ALDX versus a peer is one thing; comparing
ALDX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ALDX can fluctuate over the course of history.
With this page we aim to empower investors researching ALDX by allowing them to research the ALDX market cap history. |
Free ALDX Email Alerts:
Video: The Importance of Market Cap
